Drug-coated balloons for acute coronary syndromes.
Bruno Scheller, Simon Eccleshall
https://pubmed.ncbi.nlm.nih.gov/38949238/Actively Recruiting
Led by Institute of Cardiovascular Diseases, Vojvodina · Updated on 2026-03-30
598
Participants Needed
5
Research Sites
N/A
Total Duration
Researchers are evaluating the use of drug-coated balloons DCB compared to drug-eluting stents DES in percutaneous coronary intervention PCI for patients experiencing ST-elevation myocardial infarction STEMI. The study aims to compare these two treatments following successful preparation of the blocked artery and confirmation that all entry criteria are met. This randomized controlled trial is conducted internationally and sponsored by the Institute of Cardiovascular Diseases, Vojvodina. Patients will be randomly assigned to receive either a paclitaxel-coated balloon delivering 3.0-3.5 micrograms per square millimeter or a second-generation drug-eluting stent. The DCB group may receive a stent as a backup if the balloon treatment result is unsatisfactory. Standard implantation techniques will be used for the DES group. Randomization occurs after confirming the artery is suitable for treatment. Participants will be followed for up to two years to assess a device-oriented composite endpoint DoCE and other outcomes including bleeding complications, target vessel revascularization, and vessel failure. Evaluations will occur at one year and two years after treatment. The study does not use blinding, and participants will be monitored for safety and treatment effectiveness during this period.
CONDITIONS
Drug-Eluting Balloon or Drug-Eluting Stent in Acute Myocardial Infarction: A Randomized Controlled Trial
M
Mila Kovačević, MD, PhD
B
Branislav Crnomarković, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Institute of Cardiovascular Diseases, Vojvodina
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of acute myocardial infarction treatment
Participants undergo treatment with either a drug (paclitaxel) coated balloon or a drug-eluting stent during the intervention procedure.
1 visit (in-person)
Duration - Up to 2 years
Participants are monitored for safety and efficacy outcomes following the intervention up to 2 years.
Follow-up visits over 2 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Bruno Scheller, Simon Eccleshall
https://pubmed.ncbi.nlm.nih.gov/38949238/Soe Hee Ann, Gillian Balbir Singh, Kyung Hun Lim...
https://pubmed.ncbi.nlm.nih.gov/26824602/Franz X Kleber, Antonia Schulz, Matthias Waliszewski...
https://pubmed.ncbi.nlm.nih.gov/25349065/Xiaojiao Hao, Damin Huang, Zhaoxia Wang...
https://pubmed.ncbi.nlm.nih.gov/34154628/David Gobić, Vjekoslav Tomulić, Davorka Lulić...
https://pubmed.ncbi.nlm.nih.gov/29208251/Andreas Indermuehle, Rahul Bahl, Alexandra J Lansky...
https://pubmed.ncbi.nlm.nih.gov/23335497/Robert A Byrne, Xavier Rossello, J J Coughlan...
https://pubmed.ncbi.nlm.nih.gov/37740496/Nicola S Vos, Nick D Fagel, Giovanni Amoroso...
https://pubmed.ncbi.nlm.nih.gov/31126887/Giuseppe De Luca, Sander A Damen, Cyril Camaro...
https://pubmed.ncbi.nlm.nih.gov/31422929/Tsutomu Kawai, Tetsuya Watanabe, Takahisa Yamada...
https://pubmed.ncbi.nlm.nih.gov/34757917/Institute of Cardiovascular Diseases, Vojvodina
Lead Sponsor